Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Intangibles (2019 - 2025)

Revolution Medicines (RVMD) has 6 years of Intangibles data on record, last reported at $55.8 million in Q1 2025.

  • For Q1 2025, Intangibles fell 11.82% year-over-year to $55.8 million; the TTM value through Mar 2025 reached $55.8 million, down 11.82%, while the annual FY2024 figure was $55.8 million, 0.0% changed from the prior year.
  • Intangibles reached $55.8 million in Q1 2025 per RVMD's latest filing, roughly flat from $55.8 million in the prior quarter.
  • Across five years, Intangibles topped out at $63.3 million in Q1 2021 and bottomed at $55.8 million in Q4 2023.
  • Average Intangibles over 5 years is $59.0 million, with a median of $58.4 million recorded in 2022.
  • Peak YoY movement for Intangibles: rose 13.41% in 2021, then decreased 11.82% in 2025.
  • A 5-year view of Intangibles shows it stood at $59.9 million in 2021, then decreased by 1.79% to $58.8 million in 2022, then dropped by 5.11% to $55.8 million in 2023, then changed by 0.0% to $55.8 million in 2024, then changed by 0.0% to $55.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Intangibles were $55.8 million in Q1 2025, $55.8 million in Q4 2024, and $55.8 million in Q2 2024.